相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。New directions in the treatment of thyroid cancer
Y. Nancy You et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2007)
A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma
J. W. B. de Groot et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Two phase 1 studies of MPC-6827, a novel vascular disrupting agent (VDA), in patients with advanced solid tumors and CNS metastases
R. Kurzrock et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors
Lee S. Rosen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis
Roy S. Herbst et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Medullary thyroid cancer: therapeutic targets and molecular markers
Douglas W. Ball
CURRENT OPINION IN ONCOLOGY (2007)
Sunitinib: From rational design to clinical efficacy
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma
Alexei V. Salnikov et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Prognosis of medullary thyroid carcinoma - Demographic, clinical, and pathologic predictors of survival in 1252 cases
Sanziana Roman et al.
CANCER (2006)
Effectiveness of Hsp90 inhibitors as anti-cancer drugs
Li Xiao et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2006)
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro
Constantine S. Mitsiades et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Mechanisms of disease:: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy
Matthias Drosten et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy:: A collaborative study with the French Endocrine Tumor Group
JF Chatal et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
BAY 43-9006 inhibition of oncogenic RET mutants
F Carlomagno et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer
CJ Strock et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Trastuzumab - A review of its use in the management of HER2-positive metastatic and early-stage breast cancer
GL Plosker et al.
DRUGS (2006)
Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A
MA Skinner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
RET tyrosine kinase signaling in development and cancer
E Arighi et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
RET proto-oncogene:: A review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors
MA Kouvaraki et al.
THYROID (2005)
Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase
L Cerchia et al.
PLOS BIOLOGY (2005)
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
R Ren
NATURE REVIEWS CANCER (2005)
Medullary thyroid carcinoma: Including MEN 2A and MEN 2B syndromes
FJ Quayle et al.
JOURNAL OF SURGICAL ONCOLOGY (2005)
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors
F Carlomagno et al.
ONCOGENE (2004)
Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma
G Cuccuru et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Management of hereditary thyroid cancer in children
MA Skinner
SURGICAL ONCOLOGY-OXFORD (2003)
Antitumor capacity of a dominant-negative RET Proto-oncogene mutant in a medullary thyroid carcinoma model
M Drosten et al.
HUMAN GENE THERAPY (2003)
The soluble ectodomain of RetC634Y inhibits both the wild-type and the constitutively active Ret
L Cerchia et al.
BIOCHEMICAL JOURNAL (2003)
Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinase
G Salvatore et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
MEN2A-RET-induced cellular transformation by activation of STAT3
JJ Schuringa et al.
ONCOGENE (2001)
Improved gene transfer to neuroblastoma cells by a monoclonal antibody targeting RET, a receptor tyrosine kinase
L Yano et al.
HUMAN GENE THERAPY (2000)
Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine
M Nocera et al.
BRITISH JOURNAL OF CANCER (2000)
分享论文
